Single high-dose erythropoietin administration immediately after reperfusion in patients with ST-segment elevation myocardial infarction: results of the erythropoietin in myocardial infarction trial. - Université de Bretagne Occidentale Access content directly
Journal Articles American Heart Journal Year : 2012

Single high-dose erythropoietin administration immediately after reperfusion in patients with ST-segment elevation myocardial infarction: results of the erythropoietin in myocardial infarction trial.

Fabrice Prunier
  • Function : Author
Loïc Bière
  • Function : Author
Jean-Jacques Bauchart
  • Function : Author
Bernard Charbonnier
  • Function : Author
Olivier Genée
  • Function : Author
Patrice Guérin
  • Function : Author
Karine Warin-Fresse
Eric Durand
Antoine Lafont
  • Function : Author
Luc Christiaens
  • Function : Author
Wissam Abi-Khalil
  • Function : Author
Stéphane Delépine
  • Function : Author
Thomas Benard
  • Function : Author

Abstract

BACKGROUND: Preclinical studies and pilot clinical trials have shown that high-dose erythropoietin (EPO) reduces infarct size in acute myocardial infarction. We investigated whether a single high-dose of EPO administered immediately after reperfusion in patients with ST-segment elevation myocardial infarction (STEMI) would limit infarct size. METHODS: A total of 110 patients undergoing successful primary coronary intervention for a first STEMI was randomized to receive standard care either alone (n = 57) or combined with intravenous administration of 1,000 U/kg of epoetin β immediately after reperfusion (n = 53). The primary end point was infarct size assessed by gadolinium-enhanced cardiac magnetic resonance after 3 months. Secondary end points included left ventricular (LV) volume and function at 5-day and 3-month follow-up, incidence of microvascular obstruction (MVO), and safety. RESULTS: Erythropoietin significantly decreased the incidence of MVO (43.4% vs 65.3% in the control group, P = .03) and reduced LV volume, mass, and function impairment at 5-day follow-up (all P < .05). After 3 months, median infarct size (interquartile range) was 17.5 g (7.6-26.1 g) in the EPO group and 16.0 g (9.4-28.2 g) in the control group (P = .64); LV mass, volume, and function were not significantly different between the 2 groups. The same number of major adverse cardiac events occurred in both groups. CONCLUSIONS: Single high-dose EPO administered immediately after successful reperfusion in patients with STEMI did not reduce infarct size at 3-month follow-up. However, this regimen decreased the incidence of MVO and was associated with transient favorable effects on LV volume and function.

Dates and versions

hal-00811692 , version 1 (11-04-2013)

Identifiers

Cite

Fabrice Prunier, Loïc Bière, Martine Gilard, Jacques Boschat, Frédéric Mouquet, et al.. Single high-dose erythropoietin administration immediately after reperfusion in patients with ST-segment elevation myocardial infarction: results of the erythropoietin in myocardial infarction trial.. American Heart Journal, 2012, 163 (2), pp.200-7.e1. ⟨10.1016/j.ahj.2011.11.005⟩. ⟨hal-00811692⟩
134 View
0 Download

Altmetric

Share

Gmail Facebook X LinkedIn More